Europe Molecular Diagnostics Market worth $10.15 billion by 2031
The report "Europe Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031" is projected to grow from USD 6.05 billion in 2026 and to reach USD 10.15 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 10.9% during the forecast period.
Browse 150 market data Tables and 44 Figures spread through 200 Pages and in-depth TOC on "Europe Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-molecular-diagnostics-market-20240631.html
Some of the major factors driving the growth of the Europe molecular diagnostics market include the growing prevalence of infectious diseases & cancer, which continues to raise the demand for effective diagnosis. The greater awareness among patients and healthcare professionals regarding early diagnosis is further leading to an increase in the use of molecular testing. Along with these factors, sustained R&D investments are driving the development of new, value-added molecular assays and technologies. Increasing healthcare expenditure has also contributed to better accessibility to molecular diagnostics, thereby strengthening the wider adoption across clinical settings.
The blood, serum, and plasma segment held the largest share of the Europe molecular diagnostics market, by sample type, in 2025.
On the basis of sample type, the market is segmented into urine; blood, serum, and plasma; and other sample types. In 2025, the blood, serum, and plasma segment dominated the market, as these samples are most widely used in molecular diagnostics across multiple applications. Their suitability for a broad range of molecular technologies, consistent availability of target biomarkers, and routine use in clinical testing have resulted in higher testing volumes, supporting the segment’s leading market position.
The screening segment is expected to be the fastest-growing segment, by clinical application, during the forecast period.
Based on clinical application, the market is segmented into diagnostics and screening. Among these, screening is the fastest-growing segment, supported by the growing focus on early disease identification and the increased use of molecular testing in preventive healthcare initiatives. The wider implementation of population-based screening programs, combined with the ability of molecular diagnostics to detect conditions at an early stage, is further contributing to the rapid growth of this segment.
The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher (US), Illumina, Inc. (US),bioMérieux (France), QIAGEN N.V. (Netherlands), Hologic, Inc. (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Revvity (US), and Abbott (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
